Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Mycoses ; 63(5): 478-487, 2020 May.
Article in English | MEDLINE | ID: mdl-32125004

ABSTRACT

INTRODUCTION: Despite widespread access to antiretroviral therapy (ART), the burden of advanced HIV disease in South Africa is high. This translates into an increased risk of AIDS-related opportunistic infections, including invasive mycoses. METHODS: Using a limited number of non-culture-based diagnostic assays, we aimed to determine the prevalence of invasive mycoses and tuberculosis among hospitalised adults with very advanced HIV (CD4 counts < 100 cells/µL) at a large academic hospital. We conducted interviews and prospective medical chart reviews. We performed point-of-care finger stick and serum cryptococcal antigen lateral flow assays; serum (1 → 3) ß-D-glucan assays; urine Histoplasma galactomannan antigen enzyme immunoassays and TB lipoarabinomannan assays. RESULTS: We enrolled 189 participants from 5280 screened inpatients. Fifty-eight per cent were female, with median age 37 years (IQR: 30-43) and median CD4 count 32 cells/µL (IQR: 13-63). At enrolment, 60% (109/181) were receiving ART. Twenty-one participants (11%) had a diagnosis of an invasive mycosis, of whom 53% (11/21) had cryptococcal disease. Thirteen participants (7%) had tuberculosis and a concurrent invasive mycosis. ART-experienced participants were 60% less likely to have an invasive mycosis than those ART-naïve (adjusted OR: 0.4; 95% CI 0.15-1.0; P = .03). Overall in-hospital mortality was 13% (invasive mycosis: 10% [95% CI 1.2-30.7] versus other diagnoses: 13% (95% CI 8.4-19.3)). CONCLUSIONS: One in ten participants had evidence of an invasive mycosis. Diagnosis of proven invasive fungal disease and differentiation from other opportunistic infections was challenging. More fungal-specific screening and diagnostic tests should be applied to inpatients with advanced HIV disease.


Subject(s)
AIDS-Related Opportunistic Infections/diagnosis , HIV Infections/complications , Invasive Fungal Infections/diagnosis , AIDS-Related Opportunistic Infections/epidemiology , Academic Medical Centers , Adult , Antigens, Fungal/blood , Antigens, Fungal/urine , Cross-Sectional Studies , Cryptococcosis/diagnosis , Cryptococcosis/epidemiology , Female , HIV Infections/microbiology , Histoplasmosis/diagnosis , Histoplasmosis/epidemiology , Humans , Inpatients , Invasive Fungal Infections/epidemiology , Lipopolysaccharides/blood , Male , Point-of-Care Systems , Prevalence , Prospective Studies , South Africa , Tuberculosis/diagnosis , Tuberculosis/epidemiology
2.
Open Forum Infect Dis ; 6(10): ofz428, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31660379
4.
S Afr J Infect Dis ; 34(1): 163, 2019.
Article in English | MEDLINE | ID: mdl-34485460

ABSTRACT

Candida auris has been detected at almost 100 South African hospitals, causing large outbreaks in some facilities, and this pathogen now accounts for approximately 1 in 10 cases of candidaemia. The objective of this guideline is to provide updated, evidence-informed recommendations outlining a best-practice approach to prevent, diagnose and manage C. auris disease in public- and private-sector healthcare settings in South Africa. The 18 practical recommendations cover five focus areas: laboratory identification and antifungal susceptibility testing, surveillance and outbreak response, infection prevention and control, clinical management and antifungal stewardship.

5.
Article in English | AIM (Africa) | ID: biblio-1270729

ABSTRACT

Candida auris has been detected at almost 100 South African hospitals, causing large outbreaksinsome facilities, and this pathogen now accounts for approximately 1 in 10 cases of candidaemia. The objective of this guideline is to provide updated, evidence-informed recommendations outlining a best-practice approach to prevent, diagnose and manage C.auris disease in public- and private-sector healthcare settings in South Africa. The 18 practical recommendations cover five focus areas: laboratory identification and antifungal susceptibility testing, surveillance and outbreak response, infection prevention and control, clinical management and antifungal stewardship


Subject(s)
Antifungal Agents , Candida/epidemiology , Candida/prevention & control , Candidemia , Communicable Diseases , Disease Management , Public-Private Sector Partnerships
SELECTION OF CITATIONS
SEARCH DETAIL
...